Prof Thierry Conroy speaks to ecancer about the PRODIGE 23 phase III trial looking at total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer, presented at the ASCO virtual meeting 2020.
He explains that patients in the first arm received preoperative chemoradiation followed by surgery with TME and postoperative adjuvant therapy for 6 months.
This was compared with a second arm of 6 cycles of mFOLFIRINOX with the same chemoradiation, surgery and 3 months of the same adjuvant therapy.
Prof Conroy reports that the mFOLFIRINOX arm showed a significant increase in disease-free survival in comparison with the first arm.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.